Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Business Wire•28/09/2026•08:00 ET
0
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease
Get started
Create a free account to read the full story and Whiz Insights.